Traws Pharma (TRAW) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.37, -7.67% vs the prior close of $0.40.
- Volume 257.42K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TRAW slides 7.7% to $0.37, a 52-week low, 10 down days in a row. Closed at $0.37, -7.67% vs the prior close of $0.40. Day range $0.37–$0.41, opened at $0.40.
TRAW daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TRAW slides 7.7% to $0.37, a 52-week low, 10 down days in a row
- Closed at $0.37, -7.67% vs the prior close of $0.40. Day range $0.37–$0.41, opened at $0.40.
- Volume was 257.42K shares, 0.4x its 50-day average of 702.30K — lighter than usual.
- Price is -30.4% vs its 50-day average ($0.53) and -69.7% vs its 200-day average ($1.22).
- 52-week range $0.37–$3.23; today's close sits at 0% of that range, 88.6% below the 52-week high.
- That makes 10 straight losses.
Oct 15, 2026 — TRAW ends flat (+0.0%) to $0.40, 9 down days in a row
- Closed at $0.40, +0.00% vs the prior close of $0.40. Day range $0.39–$0.41, opened at $0.40.
- Volume was 36.90K shares, 0.1x its 50-day average of 702.96K — lighter than usual.
- Price is -25.1% vs its 50-day average ($0.53) and -67.2% vs its 200-day average ($1.22).
- 52-week range $0.39–$3.23; today's close sits at 0% of that range, 87.6% below the 52-week high.
- That makes 9 straight losses.
Oct 14, 2026 — TRAW dips 2.4% to $0.40, a 52-week low, 8 down days in a row
- Closed at $0.40, -2.44% vs the prior close of $0.41. Day range $0.39–$0.42, opened at $0.41.
- Volume was 149.40K shares, 0.2x its 50-day average of 706.24K — lighter than usual.
- Price is -25.5% vs its 50-day average ($0.54) and -67.3% vs its 200-day average ($1.22).
- 52-week range $0.39–$3.23; today's close sits at 0% of that range, 87.6% below the 52-week high.
- That makes 8 straight losses.
Oct 13, 2026 — TRAW dips 2.4% to $0.41, a 52-week low, 7 down days in a row
- Closed at $0.41, -2.38% vs the prior close of $0.42. Day range $0.41–$0.43, opened at $0.42.
- Volume was 91.20K shares, 0.1x its 50-day average of 706.39K — lighter than usual.
- Price is -24.1% vs its 50-day average ($0.54) and -66.6% vs its 200-day average ($1.23).
- 52-week range $0.41–$3.23; today's close sits at 0% of that range, 87.3% below the 52-week high.
- That makes 7 straight losses.
Oct 12, 2026 — TRAW slides 6.7% to $0.42, a 52-week low, 6 down days in a row
- Closed at $0.42, -6.67% vs the prior close of $0.45. Day range $0.41–$0.44, opened at $0.43.
- Volume was 178.40K shares, 0.3x its 50-day average of 704.44K — lighter than usual.
- Price is -22.4% vs its 50-day average ($0.54) and -65.9% vs its 200-day average ($1.23).
- 52-week range $0.41–$3.27; today's close sits at 0% of that range, 87.2% below the 52-week high.
- That makes 6 straight losses.
Oct 9, 2026 — TRAW slides 6.3% to $0.45, a 1-month low, 5 down days in a row
- Closed at $0.45, -6.25% vs the prior close of $0.48. Day range $0.43–$0.47, opened at $0.47.
- Volume was 687.20K shares, 1.0x its 50-day average of 696.30K.
- Price is -17.0% vs its 50-day average ($0.54) and -63.6% vs its 200-day average ($1.24).
- 52-week range $0.43–$3.27; today's close sits at 1% of that range, 86.2% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 — TRAW ends flat (+0.0%) to $0.48, 4 down days in a row
- Closed at $0.48, +0.00% vs the prior close of $0.48. Day range $0.46–$0.48, opened at $0.48.
- Volume was 199.60K shares, 0.3x its 50-day average of 693.08K — lighter than usual.
- Price is -11.4% vs its 50-day average ($0.54) and -61.3% vs its 200-day average ($1.24).
- 52-week range $0.43–$3.27; today's close sits at 2% of that range, 85.3% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — TRAW slides 7.7% to $0.48, a 1-month low, 3 down days in a row
- Closed at $0.48, -7.69% vs the prior close of $0.52. Day range $0.46–$0.52, opened at $0.52.
- Volume was 219.50K shares, 0.3x its 50-day average of 689.31K — lighter than usual.
- Price is -11.4% vs its 50-day average ($0.54) and -61.5% vs its 200-day average ($1.25).
- 52-week range $0.43–$3.27; today's close sits at 2% of that range, 85.3% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — TRAW slides 3.7% to $0.52
- Closed at $0.52, -3.70% vs the prior close of $0.54. Day range $0.52–$0.54, opened at $0.53.
- Volume was 125.10K shares, 0.2x its 50-day average of 688.45K — lighter than usual.
- Price is -4.1% vs its 50-day average ($0.54) and -58.4% vs its 200-day average ($1.25).
- 52-week range $0.43–$3.27; today's close sits at 3% of that range, 84.1% below the 52-week high.
Oct 5, 2026 — TRAW slides 5.3% to $0.54
- Closed at $0.54, -5.26% vs the prior close of $0.57. Day range $0.53–$0.58, opened at $0.56.
- Volume was 161.50K shares, 0.2x its 50-day average of 688.87K — lighter than usual.
- Price is -0.4% vs its 50-day average ($0.54) and -56.9% vs its 200-day average ($1.25).
- 52-week range $0.43–$3.27; today's close sits at 4% of that range, 83.5% below the 52-week high.
Oct 2, 2026 — TRAW jumps 3.6% to $0.57
- Closed at $0.57, +3.64% vs the prior close of $0.55. Day range $0.55–$0.57, opened at $0.56.
- Volume was 68.40K shares, 0.1x its 50-day average of 689.16K — lighter than usual.
- Price is +5.3% vs its 50-day average ($0.54) and -54.8% vs its 200-day average ($1.26).
- 52-week range $0.43–$3.27; today's close sits at 5% of that range, 82.6% below the 52-week high.
TRAW latest news & SEC filings
Every SEC filing by or about TRAW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2025:
- Revenue: $2.73M
- Net income: -$3.05M (prior year -$915.00K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.16 (prior year -$0.11) (loss widened vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade TRAW
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Apr 15, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.25% (largest 12.0%). That is a volatile stock.
- Liquidity: about 1.63M shares (≈$603.42K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.37 vs a range of $0.37–$3.23 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Capital Gp Viii Llc Orbimed bought 597,729 shares on Apr 16, 2026.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 14, 2026; 8-K Jul 31, 2026.
- Share count: 15.37M shares outstanding (Aug 12, 2026), +117.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TRAW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.40 | 0.41 | 0.37 | 0.37 | 257.42K |
| Oct 15, 2026 | 0.40 | 0.41 | 0.39 | 0.40 | 36.90K |
| Oct 14, 2026 | 0.41 | 0.42 | 0.39 | 0.40 | 149.40K |
| Oct 13, 2026 | 0.42 | 0.43 | 0.41 | 0.41 | 91.20K |
| Oct 12, 2026 | 0.43 | 0.44 | 0.41 | 0.42 | 178.40K |
| Oct 9, 2026 | 0.47 | 0.47 | 0.43 | 0.45 | 687.20K |
| Oct 8, 2026 | 0.48 | 0.48 | 0.46 | 0.48 | 199.60K |
| Oct 7, 2026 | 0.52 | 0.52 | 0.46 | 0.48 | 219.50K |
| Oct 6, 2026 | 0.53 | 0.54 | 0.52 | 0.52 | 125.10K |
| Oct 5, 2026 | 0.56 | 0.58 | 0.53 | 0.54 | 161.50K |
| Oct 2, 2026 | 0.56 | 0.57 | 0.55 | 0.57 | 68.40K |
| Oct 1, 2026 | 0.60 | 0.60 | 0.54 | 0.55 | 140.00K |
| Sep 30, 2026 | 0.63 | 0.68 | 0.59 | 0.59 | 332.00K |
| Sep 29, 2026 | 0.56 | 0.63 | 0.54 | 0.63 | 391.80K |
| Sep 28, 2026 | 0.53 | 0.59 | 0.53 | 0.58 | 175.50K |
| Sep 25, 2026 | 0.53 | 0.57 | 0.51 | 0.56 | 880.20K |
| Sep 24, 2026 | 0.51 | 0.70 | 0.50 | 0.56 | 28.31M |
| Sep 23, 2026 | 0.49 | 0.50 | 0.48 | 0.50 | 40.80K |
| Sep 22, 2026 | 0.49 | 0.52 | 0.49 | 0.50 | 109.10K |
| Sep 21, 2026 | 0.49 | 0.52 | 0.48 | 0.50 | 127.60K |
About Traws Pharma
Traws Pharma (TRAW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEWTOWN, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1130598.
TRAW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Werner Cautreels | Director | Jul 15, 2026 |
| Trafford Clarke | Director | Jul 14, 2026 |
| Iain D. Dukes | Chief Executive Officer | Jul 14, 2026 |
| John Harold Leaman | Director | Jul 14, 2026 |
| Jack E Stover | Director | Jul 14, 2026 |
| Nikolay Savchuk | Chief Operating Officer | Jul 15, 2026 |
| Mary Teresa Shoemaker | Director | Jul 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Iain D. Dukes | Chief Executive Officer | Jul 14, 2026 |
| Charles Nolan Parker | Chief Financial Officer | Jul 14, 2026 |
| Charles David Pauza | Chief Science Officer Virology | Jul 16, 2026 |
| Robert Redfield | Chief Medical Officer | Jul 14, 2026 |
| Nikolay Savchuk | Chief Operating Officer | Jul 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 16, 2026 | Capital Gp Viii Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Capital Gp Viii Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Advisors Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Advisors Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Capital Gp Viii Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Capital Gp Viii Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Advisors Llc Orbimed | Buy | 597,729 | $1.67 |
| Apr 16, 2026 | Advisors Llc Orbimed | Buy | 597,729 | $1.67 |
TRAW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.79M | $9.17M | 0.82 | $-18.18M |
| Dec 31, 2024 | $226.00K | $-166.52M | -35.21 | $-29.79M |
| Dec 31, 2023 | $226.00K | $-18.95M | -22.57 | $-17.93M |
| Dec 31, 2022 | $226.00K | $-18.96M | -0.91 | $-16.29M |
| Dec 31, 2021 | $226.00K | $-16.16M | -0.96 | $-19.49M |
Latest balance sheet: total assets $11.47M, total liabilities $9.78M, cash $20.56M (as of Jun 30, 2026).
TRAW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $0.57 |
| May 15, 2026 | 8-K Item 2.02 (results) | $1.88 |
| Apr 15, 2026 | 8-K Item 2.02 (results) | $1.23 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $1.77 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $1.62 |
| May 15, 2025 | 8-K Item 2.02 (results) | $1.10 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $2.30 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $5.58 |
| Aug 15, 2024 | 8-K Item 2.02 (results) | — |
| May 16, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TRAW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.